AMENDMENTS TO THE CLAIMS:

Please amend claim 50 as follows:

Please add new claims 73-82.

Please cancel claims 1-49 and 51-72 without prejudice.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-49 **(Cancelled)**

50. **(Currently amended)** A method of screening for anticancer activity comprising ~~:~~ detecting a difference between the levels of an expression product of a cancer associated (CA) gene in a cell in the presence and absence of an anticancer drug candidate, said expression product comprising a nucleotide sequence having at least 95% sequence identity to a sequence of SEQ ID NO:57, or a complement thereof, whereby a difference of at least 50% in the levels of the expression product in the presence of the anticancer drug candidate compared to the levels of the expression product in the absence of the anticancer drug candidate indicates that the anticancer drug candidate has anticancer activity

~~(a) providing a cell that expresses a cancer associated (CA) gene encoded by a nucleic acid sequence selected from the group consisting of the sequences SEQ ID NOS: 4, 16, 24, 30, 36, 42, 54, 68, 80, and 88 shown in Tables 1-10, or fragment thereof;~~

~~(b) contacting a tissue sample derived from a cancer cell with an anticancer drug candidate;~~ ~~and~~

~~(c) monitoring an effect of the anticancer drug candidate on an expression of the CA polynucleotide in the tissue sample~~ .

Claims 51-72 **(Cancelled)**

73. (New) The method of claim 50, wherein the nucleotide sequence has a sequence identity of at least about 98% with a sequence of SEQ ID NO:57, or a complement thereof.

74. (New) The method of claim 50 wherein said nucleotide sequence comprises a sequence of SEQ ID NO:57, or complement thereof.

75. (New) The method of claim 50 wherein the cell is derived from a patient sample.

76. (New) The method of screening for anticancer activity according to claim 50, wherein the drug candidate is a tyrosine kinase antagonist, a modulator of signaling, an inhibitor of cell adhesion, a stimulator of apoptosis, a modulator of amino acid transport, or a modulator of ion transport.

77. (New) The method of screening for anticancer activity according to claim 50, wherein the drug candidate is an inhibitor of transcription or expression.

78. (New) The method of claim 50 wherein the cancer is colon or prostate cancer.

79. (New) The method of claim 50 wherein the difference between the level of the expression products in the presence and absence of the anticancer drug candidate is at least 100%.

80. (New) The method of claim 50 wherein the difference between the level of the expression products in the presence and absence of the anticancer drug candidate is at least 150%.

81. (New) The method of claim 50 wherein the candidate cancer drug is selected from the group consisting of a protein, oligopeptide, small organic or inorganic molecule, polysaccharide, or polynucleotide.

82. (New) The method of claim 50 wherein the candidate cancer drug is an organic compound having a molecular weight less than about 2,500 daltons.